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ARTICLE
Cis-regulatory CYP6P9b P450 variants associated
with loss of insecticide-treated bed net efﬁcacy
against Anopheles funestus
Leon M.J. Mugenzi1,2,3, Benjamin D. Menze1,2, Magellan Tchouakui2, Murielle J. Wondji1,2, Helen Irving1,
Micareme Tchoupo2, Jack Hearn 1, Gareth D. Weedall1,4, Jacob M. Riveron1,2 & Charles S. Wondji 1,2*
Elucidating the genetic basis of metabolic resistance to insecticides in malaria vectors is
crucial to prolonging the effectiveness of insecticide-based control tools including long lasting
insecticidal nets (LLINs). Here, we show that cis-regulatory variants of the cytochrome P450
gene, CYP6P9b, are associated with pyrethroid resistance in the African malaria vector
Anopheles funestus. A DNA-based assay is designed to track this resistance that occurs near
ﬁxation in southern Africa but not in West/Central Africa. Applying this assay we demon-
strate, using semi-ﬁeld experimental huts, that CYP6P9b-mediated resistance associates
with reduced effectiveness of LLINs. Furthermore, we establish that CYP6P9b combines with
another P450, CYP6P9a, to additively exacerbate the reduced efﬁcacy of insecticide-treated
nets. Double homozygote resistant mosquitoes (RR/RR) signiﬁcantly survive exposure to
insecticide-treated nets and successfully blood feed more than other genotypes. This study
provides tools to track and assess the impact of multi-gene driven metabolic resistance to
pyrethroids, helping improve resistance management.
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Malaria remains a major public health burden in Africa.Control strategies rely predominantly on insecticide-based interventions such as indoor residual spraying
and long-lasting insecticide nets (LLINs). These tools have been
estimated to be responsible for more than 68% of the decrease in
malaria mortality in the past 15 years having helped prevent more
than 663 million clinical cases of malaria1. Increasing insecticide
resistance in malaria vector species presents a major challenge to
the continued success of public health interventions. The eluci-
dation of the molecular basis of insecticide resistance in these
vectors and its evolution across Africa is a crucial step to design
resistance management strategies to prevent potentially devas-
tating public health consequences. Detailed information on
resistance mechanisms is a prerequisite to detect resistance
markers facilitating the design of ﬁeld-applicable diagnostic tools.
Unlike current WHO bioassays that only detect resistance once it
is well established in the population2, these molecular diagnostic
tools can detect and track resistance at an early stage, which is an
essential requirement of resistance management efforts.
Resistance to insecticides is primarily caused by two major
mechanisms: target-site resistance (e.g., knockdown resistance,
kdr) and metabolic resistance through elevated expression of
detoxiﬁcation genes, especially the cytochrome P450s3,4.
Target-site resistance through knockdown resistance (kdr)
mutations in the voltage-gated sodium channel gene is well
characterised with DNA-based diagnostic tools designed since
the late 1990s5,6.
In contrast, metabolic resistance, considered to be more likely
to cause control failure7, remains—despite recent progress8–11—
poorly characterised due to the complexity of this resistance
mechanism12. This is the reason why although several cyto-
chrome P450 genes associated with pyrethroid resistance have
been reported, only a single DNA-based marker has been
detected to date13 limiting the design of ﬁeld applicable diagnostic
tools to detect and track this resistance. Indeed, progress was
recently made with the detection of the ﬁrst DNA-based P450
resistance marker in mosquitoes in the CYP6P9a gene on the rp1
(resistance to pyrethroid 1) quantitative trait locus (QTL)14,15
allowing assessment of the impact of metabolic resistance on the
effectiveness of insecticide-treated nets13.
However, the CYP6P9a marker does not explain all of the
genetic variance in pyrethroid resistance and is currently only
present in southern Africa13,16,17. Thus, there is a need to
characterise the molecular basis of pyrethroid resistance Africa-
wide and detect related genetic variants so that DNA-based
diagnostic assays can be designed to enhance our ability to detect
resistance and rigorously characterise the impact on insecticide-
based interventions.
To tackle the molecular complexity of metabolic resistance to
pyrethroids and detect resistance markers and design reliable
diagnostic assays, we carry out large scale transcriptional and
genomic proﬁling of Anopheles funestusmosquitoes across Africa.
Our results reveal the complex and diverse molecular changes
underlying insecticide resistance across the species’ range char-
acterised by differential gene expression patterns and genomic
signatures, notably transcription factor binding sites (cis-acting
regulatory elements) regulating expression of detoxiﬁcation
genes. This thorough elucidation of metabolic resistance leads to
the detection of a P450 DNA-based marker in the CYP6P9b gene
from which a simple ﬁeld-applicable polymerase chain reaction
(PCR) diagnostic assay is designed. Field assessment of the
impact of pyrethroid resistance using this marker in semi-ﬁeld
conditions in experimental huts revealed that this metabolic
resistance marker in combination with the other P450 marker
(CYP6P9a) is associated with exacerbated loss of efﬁcacy of
insecticide-treated nets.
Results
Transcription analysis of resistant An. funestus Africa-wide.
Previous efforts to detect genes associated with pyrethroid resis-
tance Africa-wide have compared mosquitoes alive after perme-
thrin exposure to the lab-susceptible FANG strain only13. A
limitation of this approach is that the over-expressed genes might
not be necessarily linked to resistance but rather other differences
in genetic background. Therefore, to detect potential genes
associated with pyrethroid resistance across Africa [Southern
(Malawi), East (Uganda), Central (Cameroon) and West
(Ghana)], we used here two additional approaches by ﬁrst com-
paring permethrin-resistant mosquitoes from one country to
permethrin-resistant mosquitoes from another country to detect
the genes speciﬁc for each region of Africa. Second, we performed
in Malawi a triangular comparison of the expression patterns of
mosquitoes alive after exposure (R) to those not exposed (Con-
trol; C) as well as the lab-susceptible strain FANG (S).
Comparisons of the transcription proﬁles between the four
African regions were performed to detect or conﬁrm genes
differentially expressed according to their resistance background.
When the southern Africa population (Malawi) is compared to all
other regions directly, the striking difference is the high up-
regulation of two P450 genes CYP6P9a and CYP6P9b in Malawi
with fold change (FC) of 28.3, 22.7 and 9.5 greater than in
Cameroon, Uganda and Ghana for CYP6P9a (Supplementary
Data 1). Both genes result from a recent duplication event14. A
similar but lower difference is observed for CYP6P9b with FC
values of 5.5, 3.4 and 3.5, respectively. In contrast to CYP6P9b,
CYP6P9a is also signiﬁcantly more over-expressed in Ghana
compared to Cameroon and Uganda. The southern Africa
mosquito population has more genes signiﬁcantly up-regulated
than other regions including cytochrome P450s, CYP4H25,
CYP4H28, CYP9J11 (except Ghana) and CYP6P2 (except
Cameroon) although the FC is much lower than for the
duplicated genes. Two cuticular protein genes, potentially
involved in cuticular resistance (AFUN005672 and
AFUN009940) were also signiﬁcantly over-expressed in Malawi
compared to the three other regions (Supplementary Data 1).
The biggest difference between the West African sample of
Ghana and others was the duplicated CYP6P4a and CYP6P4b that
are signiﬁcantly more up-regulated in Ghana than other regions
with FC values of 25.8, 7.6 and 21.2 for CYP6P4a, respectively,
against Cameroon, Malawi and Uganda or FC values of 22.7, 6.5
and 9 for CYP6P4b. These genes are also signiﬁcantly more
expressed in mosquitoes from southern Africa than in Central
and East Africa.
The Central African population of Cameroon exhibited a
greater difference than other regions for the cytochrome P450
CYP325A gene with FC values of 5.3, 12.1 and 4.5 against Malawi,
Uganda and Ghana, respectively, although the overall abundance
of reads for this gene is lower (<500). The carboxylesterase gene
AFUN002514 was also signiﬁcantly overexpressed in Cameroon
compared to the south (FC 3.8) and the east (FC 4.7) but not
against Ghana where it is also over-expressed compared to
Malawi (FC 2.5) and Uganda (FC 3.3). This suggests that the
over-expression of the carboxylesterase AFUN002514 is speciﬁc
to West-Central Africa.
The East African population from Uganda exhibited the
greatest difference in expression to all other regions for the
cytochrome P450 CYP9K1 with FC values of 4.6, 2.6 and 1.8
against Cameroon, Malawi and Ghana suggesting that this gene is
potentially speciﬁc to pyrethroid resistance in the East Africa
region. The P450 CYP307A1 is also up-regulated in Uganda
relative to other regions (Supplementary Data 1). Further
differences between regions are highlighted in Supplementary
Note 1.
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In addition, a triangular analysis of transcriptional proﬁles
between resistant (R), unexposed control (C) and susceptible (S)
mosquito samples in Malawi conﬁrmed the major role potentially
played by CYP6P9a and CYP6P9b in these countries with a
slightly higher level in R–S compared to C–S (FC 60.1 vs. 57.1 for
CYP6P9a; FC 23.7 vs. 18.5 for CYP6P9b) (Supplementary Table 1;
Supplementary Note 2). Moreover, the quantitative reverse
transcription (qRT) PCR expression patterns broadly supported
the differences observed with RNAseq in the main genes driving
pyrethroid resistance in different African regions (Fig. 1;
Supplementary Note 3).
Genetic polymorphisms of CYP6P9b-mediated resistance. To
detect potential genetic variants associated with pyrethroid
resistance, we focused our attention on the CYP6P9b P450
because this gene was highly over-expressed in resistant mos-
quitoes especially in southern Africa and after the recent char-
acterisation of CYP6P9a, the other over-expressed gene in
southern Africa13.
To have a full view of the potential regulatory elements driving
the over-expression of CYP6P9b, we ampliﬁed and sequenced the
full 1 kb intergenic region (Supplementary Fig. 1; Supplementary
Note 4) between CYP6P9b and CYP6P5 in individual resistant
(FUMOZ_R) and susceptible (FANG) mosquitoes. An indel of 3
bp (AAC) was consistently observed with deletion in the resistant
FUMOZ and presence in susceptible FANG. The core promoter
elements detected using GPminer include TATA boxes (8 in
FUMOZ and 7 in FANG and 1 GC box in each strain), 1 GC box
and 1 CCAAT box. The CYP6P9b promoter also exhibits two
sites for the putative arthropod initiator (Inr) contrary to one for
the 800 bp promoter fragment of CYP6P9a previously studied13.
Furthermore, several transcription factor binding sites were
detected including six sites for the CncC nrf2/MAF (in both
strains) and several sites for GATA, MYB or AHR transcription
factors.
The polymorphism pattern of the promoter region of CYP6P9b
was also assessed Africa-wide by sequencing the 1 kb intergenic
region in mosquitoes from West, Central, East and Southern
Africa. All populations from southern Africa (Mozambique,
Malawi and Zambia) exhibited a low genetic diversity with
Mozambique presenting the least diverse set with a number of
haplotype (h)= 2 and a haplotype diversity (hd)= 0.189.
However, the population of Benin (West Africa) exhibited no
segregating sites with only a single haplotype observed. This
absence of polymorphism in Benin (similar for CYP6P9a)
contrasts highly with neighbouring populations notably that of
Nigeria which exhibits the highest diversity (40 segregating sites,
h= 13; hd= 0.95) (Supplementary Table 2).
Overall, southern Africa populations consistently exhibited a
different polymorphism pattern to other regions notably with the
presence of an AAC deletion 50 bp upstream of nrf2/MAF
binding sites and 72 bp from a CCAAT box. The AAC deletion
located 703 bp from start codon is tightly associated with other
polymorphisms in a haplotype (STH13) (Supplementary Fig. 2).
This haplotype predominates in southern Africa (68/82) reﬂect-
ing the marked selective sweep observed around this gene in this
region18. A maximum likelihood phylogenetic tree of all
haplotypes (Fig. 2a) revealed three broad clusters corresponding
to southern Africa, West and Central Africa; the unique Benin
haplotype is different from other West Africa haplotypes and is
closer to the Central Africa Cluster (Fig. 2a).
The difference in genetic diversity between southern Africa and
other regions was further supported by the higher genetic
differentiation between these populations as shown by the
neighbour-joining tree of the genetic distance (NST estimates)
(Fig. 2b). A haplotype network built with the Templeton,
Crandall and Sing (TCS) programme, further highlights the
reduced diversity in southern Africa with the predominant
STH13 haplotype in all populations from this region (Fig. 2c);
greater diversity is seen in other samples with a high number of
mutational steps between haplotypes observed particularly in
Nigeria. Nevertheless, other countries such as Benin and Ghana
also have a predominant haplotype suggesting possible selection
also acting on this gene or in nearby genes in these locations.
To assess whether the differences observed in the 5’UTR region
of CYP6P9b between southern Africa and other regions could
have resulted from selection due to insecticide pressure, we
assessed the polymorphism of the 1 kb fragment of CYP6P9b in
samples collected before the scale-up of LLINs in Mozambique
(2002) and samples collected after scale-up (2016). This 1 kb
fragment was polymorphic before scale-up with many segregating
sites (18) and haplotypes (h= 6; hd= 0.797) as well as high
nucleotide diversity (π= 0.011) (Supplementary Table 2; Fig. 2d).
In contrast, the post-intervention samples exhibited very low
diversity with low haplotypes number (h= 2; hd= 0.189) and
reduced nucleotide diversity (π= 0.0053). Construction of
the maximum likelihood tree further highlights the contrast
between both sets of samples as the pre-intervention mosquitoes
cluster together and become more diverse (Fig. 2d). In contrast,
the post-intervention samples cluster noticeably away from the
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pre-intervention with a drastically reduced haplotype number.
The TCS haplotype network further supported the drastic
difference between pre- and post-intervention samples with more
mutational steps observed between pre-intervention haplotypes
whereas a highly predominant haplotype is observed in post-
intervention samples (18/20). This is not observed in the pre-
intervention samples, which is probably an indication of its low
frequency before bed nets (Fig. 2e). Furthermore, the AAC motif
now undetectable in the southern populations and located 50 bp
upstream of a nrf2/MAF binding site was present in all pre-
intervention samples suggesting that this deletion plays a role in
the regulation of CYP6P9b. These major differences between pre-
and post-intervention samples show that scale up of insecticide-
treated nets is likely a major factor that has driven this evolution
in An. funestus populations in southern Africa.
CYP6P9b promoter analysis detects resistance variants. The 1
kb fragment upstream of the translation start site of CYP6P9b was
assessed for its promoter activity using a luciferase assay in the
An. gambiae 4a-2 cell line. To narrow down the regions con-
taining the potential regulatory motifs, six different sized frag-
ments of the 1 kb, 600 base pairs (bp), 400 bp, 300 bp, 100 bp and
80 bp immediately upstream of the translation start codon from
both the resistant FUMOZ and the susceptible FANG strain were
cloned upstream of a reporter gene in a pGL3 vector. These
constructs were used in luciferase reporter gene assays but did not
show a signiﬁcant difference in the relative luciferase activity of
the 1 kb insert between the two strains. Similarly, the shorter
versions of the putative promoter did not present a signiﬁcantly
different activity between these two strains. Nevertheless, the
progressive truncation of the 1 kb insert helped identify the major
regulatory elements in either strain. Shortening the promoter
fragment to 600, 400 and 300 bp reduced their activity in
FUMOZ by 49.9 (P < 0.0001; unpaired t test), 21.1 (P= 0.0074;
unpaired t test) and 39.0% (P= 0.0043; unpaired t test) respec-
tively, and similarly in FANG with reductions of 54.4 (P= 0.0014;
unpaired t test), 57.6 (P < 0.0001; unpaired t test) and 57.7 (P <
0.0001; unpaired t test), respectively (Fig. 3a). However, for both
strains, a much higher reduction in luciferase activity is seen
when the promoter fragment is further truncated to just 100
(>91%) and 80 bp (>93%) (P < 0.0001; unpaired t test) with
deletion of all regulatory elements including CncC nrf2/MAF and
CCAAT boxes (Fig. 3a).
A DNA-based diagnostic tool to detect CYP6P9b resistance. To
design a DNA-based diagnostic assay to detect CYP6P9b-medi-
ated resistance, we screened the 1 kb for suitable restriction sites
in complete linkage with the AAC deletion in the resistant
mosquitoes across southern Africa including in the FUMOZ
strain (Supplementary Fig. 3a). This allowed the design of a
simple PCR restriction fragment length polymorphism (RFLP).
We found a restriction site for the NmuCl (Tsp45I) (cut site 5′-
GTSAC-3′) spanning a C/T mutation located 11 bp downstream
of the AAC deletion and designed a PCR-RFLP that, in mos-
quitoes carrying the CYP6P9b variants associated with suscept-
ibility to insecticides, cuts the 550 bp amplicon in two fragments
of 400 and 150 bp, whereas the amplicon carrying the resistance-
associated allele remains uncut (Fig. 3b; Supplementary Fig. 3b).
To assess the efﬁcacy of this diagnostic assay, we genotyped the
FUMOZ-R and FANG strains for the CYP6P9b-R marker and
establish that all 50 tested FUMOZ-R mosquitoes were homo-
zygote resistant RR whereas all the FANG were homozygote
susceptible SS.
To further validate the ability of CYP6P9b_R marker to predict
pyrethroid resistance phenotype in An. funestus, mosquitoes were
crossed between FUMOZ and FANG at the F8 generation.
Genotyping of the same mosquitoes previously used to validate
the CYP6P9a13 revealed that those surviving exposure to
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permethrin for 180 min are predominantly homozygote resistant
(10/48) and heterozygotes (36/48) with two bearing the homo-
zygote susceptibility genotype. From the 47 dead mosquitoes after
30 min exposure to permethrin (highly susceptible), 46/47 were
homozygote susceptible and one heterozygote (Supplementary
Fig. 3c). A signiﬁcant association was observed between
permethrin resistance and the CYP6P9b genotype with a highly
signiﬁcant odds ratio when comparing RR vs. SS (OR= inﬁnity;
P= 1.1 × 10−50, Fisher’s exact test) and RS vs. SS (OR= 715; P=
2.4 × 10−45, Fisher’s exact test) (Fig. 3c).
The contribution of CYP6P9b to pyrethroid resistance was also
compared to that of CYP6P9a revealing that both genes combine
additively to confer higher level of resistance. Indeed, all
mosquitoes with the double homozygote resistant genotypes
(RR/RR) were alive after 180 min exposure. However, only half of
the homozygous resistance-genotype carriers for CYP6P9b also
had the homozygous resistant genotype for CYP6P9a with the
other half being only heterozygous for CYP6P9a (Supplementary
Fig. 3d). 66.7% of mosquitoes that survived were double
heterozygous (RS/RS), whereas only 10.4% were RR/RR carriers
and 16.7% RR/RS carriers (Fig. 3d: Supplementary Fig. 3d)
suggesting possible ﬁtness cost associated with possessing double
resistance alleles for both genes. None of the dead mosquitoes had
RR/RR, RR/RS or RS/RS genotypes; this shows a strong
correlation with permethrin resistance with high OR (inﬁnity;
P < 0.0001, Fisher’s exact test).
Distribution of the resistant CYP6P9b allele across Africa.
Genotyping of the CYP6P9b was successful in most countries, but
some samples failed to amplify in Kenya, Uganda, Cameroon and
DR Congo (western region only). It is possible that a structural
variant is present in these countries preventing the ampliﬁcation
of the 550 bp fragment. The CYP6P9b resistant allele
(CYP6P9b_R) is detected throughout southern Africa at a very
high frequency (>90%) with ﬁxation observed in Mozambique
(Fig. 4a), consistent with previous results from CYP6P9a19. An
intermediate frequency is observed in Tanzania (63.4% for
CYP6P9b_R) and in Eastern Democratic Republic of Congo
(66.6%). CYP6P9b_R is absent from other parts of Africa
including East (Kenya, Uganda), Central (Democratic Republic of
Congo (DRC)-West, Cameroon) and West Africa (Fig. 4b).
Furthermore, the potential association of CYP6P9b_R with
CYP6P9a_R in ﬁeld populations was assessed in Tanzania and
DRC where there is segregation of these genotypes. This implies
that there is a greater linkage of CYP6P9a and CYP6P9b geno-
types in Tanzania with 71.8% of identical genotypes; this is much
lower in DRC where only 51% identical genotypes are observed
between the two genes in assessed mosquitoes (Fig. 4c). However,
the RS/RS genotype is predominant (>36%) in both countries
with double homozygote resistant RR/RR being higher in Tan-
zania (28.5%) than DRC (16.7%).
CYP6P9b_R associated with reduced efﬁcacy of insecticide-
treated nets. The impact of the CYP6P9b resistance allele on the
effectiveness of conventional (PermaNet 2.0) and PBO-based
(PermaNet 3.0) nets was assessed using a release-recapture of
mosquitoes from the hybrid strain between highly resistant
FUMOZ-R and fully susceptible FANG as described for
CYP6P9a13. Mosquitoes from FANG/FUMOZ crosses (F4) were
moderately resistant to pyrethroids with mortality rates of >70%
for both permethrin and deltamethrin after 1 h exposure.
To assess the impact of CYP6P9b on the efﬁcacy of LLINs, we
ﬁrst analysed this impact on the mortality of mosquitoes after
exposure to PermaNet 2.0 because the number of live mosquitoes
was too low with PermaNet 3.0. Both nets are impregnated with
deltamethrin. The association between CYP6P9b genotypes and
the ability to survive exposure to PermaNet 2.0 was ﬁrst assessed
using only mosquitoes collected in the room and unfed to avoid
possible bias due to feeding or exophily status. This analysis
revealed a signiﬁcant difference in the distribution of genotypes
between dead and live mosquitoes (chi square= 1180; P < 0.0001,
chi-square) (Fig. 5a). Comparing the proportion of different
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genotypes according to mortality outcome revealed that CYP6P9b
homozygote resistant (RR) were signiﬁcantly more able to survive
exposure to PermaNet 2.0 than homozygotes-susceptible mos-
quitoes (OR= 109.3; CI= 40.7–293.2; P < 0.0001, Fisher’s exact
test) (Table 1). This correlation is even stronger than previously
observed for CYP6P9a in the same mosquitoes (OR= 34.9; CI=
15.8–77.1; P < 0.0001, Fisher’s exact test)13.
Similarly, heterozygote mosquitoes (RS) survived exposure to
PermaNet 2.0 signiﬁcantly better than homozygote susceptible
(SS) (OR= 34.7; CI= 14.6–82.5; P < 0.0001, Fisher’s exact test).
The additive resistance conferred by each allele of CYP6P9b was
shown by the fact that homozygote resistant mosquitoes (RR)
could also survive better than heterozygotes (OR= 3.14; CI=
1.4–6.9: P= 0.0058, Fisher’s exact test). Overall, the strength of
this association was further shown by the signiﬁcant ability to
survive exposure when possessing a single CYP6P9b-resistant
allele (R) compared to the susceptible allele (S) (OR= 7.2; CI=
3.813.4; P < 0.0001, Fisher’s exact test) (Fig. 5b). A similar pattern
of signiﬁcant correlation between CYP6P9b genotypes and
mortality was also observed when analysing all the dead and
live samples regardless of blood feeding and exophilic status but
with a lower OR value (Table 1).
The impact of the CYP6P9b_R was also assessed on the ability
to blood feed against PBO-based net (PermaNet 3.0). A
signiﬁcant difference was observed in the distribution of
CYP6P9b genotypes between blood-fed and unfed mosquitoes
when exposed to PermaNet 3.0 (chi square= 28.8; P < 0.0001,
chi-square). This resulted in a signiﬁcant association between
CYP6P9b genotypes and the ability to blood feed with homo-
zygote resistant (RR) mosquitoes feeding signiﬁcantly more than
homozygote susceptible (SS) mosquitoes (OR= 5.04: CI=
1.7–14.6; P= 0.0001, Fisher’s exact test). This is also true for
homozygote resistant (RR) when compared to heterozygotes
(OR= 2.4: CI= 1.3–4.39; P= 0.0085, Fisher’s exact test). No
signiﬁcant difference was observed between heterozygotes and
susceptible genotype (Table 1). However, CYP6P9b did not
impact blood feeding when mosquitoes were exposed to
PermaNet 2.0, and no difference was observed for the control
net (Fig. 5c; Table 1). No signiﬁcant association was observed for
PermaNet 2.0 (Supplementary Fig. 4a) or in the control untreated
net (Supplementary Fig. 4b).
Combined effect of CYP6P9b and 6P9a on LLIN efﬁcacy. As
CYP6P9b genotypes were shown to be independent from those of
CYP6P9a, we next assessed how combinations of genotypes at
both genes impact the efﬁcacy of LLINs focusing on PermaNet
2.0 for mortality and PermaNet 3.0 for blood feeding. Analysis of
the impact of combined genotypes on mortality with PermaNet
2.0 conﬁrmed the independent segregation of genotypes at both
genes with several combinations of genotypes observed including
RR/RR, RR/RS, RS/RS, RS/SS and SS/SS (Fig. 6a). A comparison
of the distribution of both sets of genotypes revealed that double
homozygote resistant (RR/RR) mosquitoes at both genes had a far
greater ability to survive exposure to PermaNet 2.0 than all other
combinations. This shows that both genes act additively to confer
a greater resistance to pyrethroids associated with a higher
reduction of bed net efﬁcacy when mosquitoes are double resis-
tant. The additive resistance was further supported in that RR/RR
mosquitoes had the greatest ability to survive exposure to Per-
maNet 2.0 when compared to double susceptible (SS/SS) (OR=
76.5; CI= 15.1–387.7) when considering all samples. There was
even greater correlation if only considering unfed mosquitoes in
the room (Fig. 6b). A signiﬁcantly increased survival is also
observed in RR/RR when compared to other combinations
although with a lower odds ratio, such as against RS/SS (OR=
47.7; P < 0.0001, Fisher’s exact test), against RR/SS (OR= 6.1;
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P= 0.01, Fisher’s exact test) and against RS/RS (OR= 3.2; P=
0.042, Fisher’s exact test). No signiﬁcant difference was observed
between RR/RR and RR/RS (OR= 1.6; P= 0.82, Fisher’s exact
test) (Fig. 6b). A similar trend is observed when comparing
homozygote resistant mosquitoes to one gene and heterozygote to
the other (RR/RS) against other combinations although at a lower
strength (Fig. 6c). No signiﬁcant difference is observed between
RR/RS and RS/RS suggesting that having one resistance-
associated allele of each gene is as good as having homozygote
resistance for one gene.
Overall, a gradual decrease of impact is seen for genotypes RR/
RR > RR/RS > RS/RS > RR/SS > RS/SS > SS/SS. Analysis of the
combined genotype distribution for blood feeding (Fig. 6d) also
revealed a signiﬁcantly increased ability to blood feed for double
homozygote-resistant mosquitoes when exposed to PermaNet 3.0
with the highest signiﬁcance against double homozygote
susceptible (OR= 6.5; P < 0.0001, Fisher’s exact test) (Fig. 6e;
Supplementary Table 3). No signiﬁcant association was observed
for PermaNet 2.0 (Supplementary Fig. 4c) and in the control
untreated net (Supplementary Fig. 4d).
Discussion
The detection of the resistance markers associated with CYP6P9b
over-expression described here provides a tool to monitor pyre-
throid resistance in ﬁeld populations of the major malaria vector
An. funestus. In addition, it also allows the assessment of the
interplay between P450 genes in their overall genetic variance to
resistance as seen here between CYP6P9a and CYP6P9b. Overall,
this study established key insights regarding the molecular basis
of pyrethroid resistance in malaria vectors in Africa.
Genomic analyses performed in this study suggest differences
in the genomic evolution of metabolic resistance to pyrethroids
across Africa: mosquitoes from different geographic regions
exhibited speciﬁc sets of genes and genetic variants associated
with resistance. The comparative RNAseq-based transcription
proﬁling between regions revealed key differences in the level of
expression of major resistance genes, including CYP6P9a and
CYP6P9b which are highly expressed in southern Africa. This
difference in gene expression is in line with previous
reports11,13,17. Other genes predominate in other regions with
CYP9K1 in Uganda, CYP6P5 and CYP325A in Central Africa
(Cameroon) and CYP6P4a/b in Ghana (West Africa). The resis-
tance proﬁle does not reﬂect the relatedness between popula-
tions13 suggesting each population independently evolves
resistance mechanisms. This contrasting expression proﬁle also
supports previous observations16 and highlights the challenges in
designing diagnostic tools for metabolic resistance in the face of
Table 1 Correlation between genotypes of CYP6P9b and mortality and blood feeding after exposure to insecticide-treated nets in
experimental huts
OR P value CI OR P value CI
Mortality
PermaNet 2.0 CYP6P9a CYP6P9b
Unfed RR vs. SS 34.9 <0.0001 15.8–77.1 109.3 <0.0001 40.7–293.2
RS vs. SS 19.9 <0.0001 9.7–40.9 34.7 <0.0001 14.6–82.5
RR vs. RS 1.75 0.26 0.81–3.8 3.14 0.0058 1.4–6.9
R vs. S 6.25 <0.0001 3.3–11.7 7.2 <0.0001 3.8–13.4
All samples RR vs. SS 10.8 <0.0001 5.6–20.8 62.1 <0.0001 23.6–163.6
RS vs. SS 5.3 <0.0001 2.8–9.8 21.9 <0.0001 8.7–55.1
RR vs. RS 2.04 0.0002 1.1–3.7 2.8 0.0025 1.48–5.2
R vs. S 3.17 0.02 1.78–5.65 4.7 <0.0001 2.6–8.7
Blood feeding
PermaNet 2.0 RR vs. SS 1.75 0.19 0.82–3.7 1.29 0.54 0.58–2.9
RR vs. RS 2.5 0.052 1.09–5.75 0.92 0.5 0.49–1.7
RS vs. SS 0.7 0.67 0.28–1.7 1.68 1 0.79–3.5
R vs. S 1.43 0.26 0.82–2.5 0.94 1 0.5–1.6
PermaNet 3.0 RR vs. SS 4.54 <0.0001 2.3–8.7 5.04 <0.0001 1.7–14.6
RR vs. RS 2.6 0.0012 1.43–4.7 2.4 0.0085 1.31–4.39
RS vs. SS 1.74 0.17 0.87–3.47 2.1 0.3 0.73–6.03
R vs. S 2.14 0.18 1.17–3.19 4.1 <0.0001 2.2–7.5
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Fig. 5 Impact of the CYP6P9b-based metabolic resistance on bed nets’
efﬁcacy. a Distribution of CYP6P9b genotypes between dead and alive
mosquitoes after exposure to PermaNet 2.0 net in experimental huts
showing that CYP6P9b_R signiﬁcantly allows mosquitoes to survive
exposure to this insecticide-treated net. b Association between frequency
of CYP6P9b-R and ability to survive exposure to PermaNet 2.0.
c Distribution of CYP6P9b genotypes between blood-fed and unfed
mosquitoes after exposure to the PBO-based net PermaNet 3.0 showing
that CYP6P9b_R allele increases the ability to take a blood meal. Source
data are provided as a Source Data ﬁle
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such molecular plasticity of populations of malaria vectors.
However, some of the differences observed between geographic
regions could be the consequence of differences in genetic
background between populations rather than just insecticide
resistance. Further functional characterisation of these over-
expressed genes both in vivo and in vitro16 will allow to conﬁrm
their role in resistance.
The detection of another P450 DNA-based marker in this
study is a great progress in our efforts to detect and track the
spread of metabolic resistance to insecticides in malaria vectors.
The mutation associated with resistance here is located in the cis-
regulatory region as established for CYP6P9a13 or for previous
observations in the mosquito Culex quinquefasciatus20 and in
Drosophila21. Similarly, the CYP6P9b AAC indel resistance
mutation is associated with transcription factor binding sites
notably to the insect ortholog of the mammalian transcript factor
Nrf2, Cap ‘n’ Collar isoform-C (CncC) with Maf-S; these regulate
transcription of detoxiﬁcation genes in several insects22. This
suggests that more attention should be paid to cis-regulatory
regions to detect potential causative mutations that could drive
resistance although this is not the unique mechanism as trans-
acting regulatory loci12 or allelic variations of resistance genes9
may also be involved.
Because of the physical proximity of CYP6P9b to CYP6P9a,
one could have assumed that both genes might be in complete
linkage disequilibrium and any marker on one of the genes will
fully explain resistance associated with the other. However, our
data suggest otherwise; while we observed signiﬁcant co-
occurrence of resistance alleles in both genes, the genotypes at
both genes can segregate independently and we observe increased
pyrethroid resistance in mosquitoes with the combined genotype.
The percentage of linkage between both genotypes varies sig-
niﬁcantly from nearly 100% in southern Africa to 71% in the East
(Tanzania) and 51% in DRC. This suggests that both genotypes
are not fully physically linked. The higher proportion of linked
genotypes in southern Africa and Tanzania is possibly a result of
a greater selection acting on this population as seen in southern
Africa where proportion of identity is close to 100% and where
high level of resistance has been reported23,24.
The independent segregation between CYP6P9a and
CYP6P9b is also observed in the lab—the hybrid strain between
the lab-resistant FUMOZ and lab-susceptible FANG exhibited
signiﬁcant independent genotypes for both genes at the F4
generation. Therefore, the availability of the CYP6P9b_R diag-
nostic assay developed here is an important tool that should
increase our ability to detect and track the spread of resistance.
Moreover, when combined with CYP6P9a_R, it could help to
assess the risk of multi-gene driven high-resistance in this
malaria vector. The current P450 diagnostic tools should allow
control programmes to monitor both P450 alleles to track
escalating pyrethroid resistance intensity in the ﬁeld. This
marker only applies to An. funestus and not to other malaria
vectors including those of the An. gambiae complex. However,
because CYP6P3, an ortholog of CYP6P9a/b, has also been
shown to play an important role in insecticide resistance in An.
gambiae, the results described here can serve as a model to
detect similar markers in other malaria vectors, speciﬁcally of
this species complex.
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The experimental hut study performed here assessed the
impact of CYP6P9b and revealed that CYP6P9b is associated with
reduced efﬁcacy of bed nets, particularly pyrethroid-only nets,
independent of CYP6P9a13. However, the key message from this
study is that a greater reduction of bed net efﬁcacy is observed
when the CYP6P9b resistant genotype combines with the
CYP6P9a resistant genotype because double homozygote resistant
mosquitoes survived exposure to pyrethroid-only nets much
better than all other genotypes tested.
This shows the great risk that metabolic resistance poses to
insecticide-based interventions as highlighted in the WHO global
plan for insecticide-resistance management which states that if
nothing is done pyrethroid resistance could lead to an increase
burden of malaria in Africa2. This concern is further supported
by a recent report from the 2018 World Malaria Report indicating
that after nearly two decades of continued decline, malaria cases
have signiﬁcantly increased in 201725. The spread of both
CYP6P9b_R and CYP6P9a_R alleles poses a signiﬁcant risk to the
effectiveness of control programmes notably in southern Africa
where both alleles are nearing ﬁxation. The diagnostic tools
designed here should help track their spread and help anticipate
the management of such resistance. PBO-based nets (here Per-
maNet 3.0) are far more effective against such populations than
pyrethroid-only nets, as also recently revealed in ﬁeld trials in
Tanzania26. Nevertheless, the high blood-feeding ability of resis-
tant mosquitoes even against PBO-nets suggests that metabolic
resistance affects the efﬁcacy of such nets and calls for the
development of other management options, for example nets that
do not rely on pyrethroids. Our experimental hut trial study is
based on a test with hybrid strains from two laboratory strains
and the impact of the resistance alleles described here on the
efﬁcacy of LLINs in natural populations remains to be estab-
lished, work that must be undertaken urgently.
In conclusion, this study used a comprehensive transcriptomic
and targeted genomic approach to detect a P450-based resistance
marker and designed a simple PCR assay to detect and track
P450-mediated metabolic resistance to pyrethroid in the major
malaria vector An. funestus in Africa. We show that the
CYP6P9b_R resistance allele described here can combine with the
previously detected CYP6P9a_R19 present on the same rp1 QTL,
conferring greater insecticide resistance in our bed nets test than
either resistance genotype in isolation. Out of the tested popu-
lations, we detected this allele only in southern and eastern
African mosquito populations. The greater reduction of efﬁcacy
of insecticide-treated nets observed in double-resistant mosqui-
toes is a major concern for the sustainability of insecticide-based
interventions solely relying on pyrethroids. Therefore, PBO-based
nets should be preferably deployed for greater impact while
encouraging the development of alternative mosquito manage-
ment options in malaria-endemic regions.
Methods
Collection and rearing of mosquitoes. The two An. funestus laboratory colonies
used here are the FANG colony—a completely insecticide-susceptible colony ori-
ginating from Angola—and the FUMOZ colony derived from southern Mozam-
bique that is highly resistant to pyrethroids and carbamates27. Mosquito collection
was performed to cover the four main regions in sub-Saharan regions: southern
(Malawi, Chikwawa (16°1’ S, 34°47’ E) in 201428), eastern (Uganda, Tororo (0°45’
N, 34°5’ E) 201429), central (Cameroon, Mibellon (6°46′ N, 11°70′ E) in 201530),
and west (Ghana, Obuasi (5°56′ N, 1°37′ W) in 201431) across the continental
range of An. funestus as recently described13. Overall, blood-fed, gravid females
were collected indoor in houses using electric aspirators between 06:00 AM-
10.00AM in each location. Females were left to become fully gravid for 4 days and
then introduced into 1.5 ml Eppendorf tube to lay eggs following the forced-egg
laying method32. Larvae were reared to generate F1 adults and used for WHO
bioassays as done by Weedall et al13. These populations are all resistant to pyre-
throids and as well as to other insecticide classes28–31. Morphological and mole-
cular identiﬁcations were performed to establish the species following Weedall
et al.13.
RNA extraction with library preparation and sequencing. The total RNA from
three pools of ten female mosquitoes (alive after 1 h permethrin exposure) was
extracted using the Arcturus PicoPure RNA isolation kit (Life Technologies,
Carlsbad, CA, USA), according to the manufacturer’s instructions. This included a
DNase treatment step. The total RNA was depleted for ribosomal RNA (rRNA)
with Ribo-Zero low input kit for human/mouse/rat (Epicentre, Madison, WI, USA)
using 100 ng of starting material. The Ribo-Zero mRNA-enriched material was
used to prepare RNAseq libraries with the ScriptSeq v2 RNAseq library preparation
kit (Epicentre) (15 cycles of PCR ampliﬁcation). Agencourt AMPure XP beads
(Beckman and Coulter, Beverly, MA, USA) were used to purify the libraries fol-
lowed by a quantiﬁcation using a Qubit ﬂuorometer (Life Technologies). The size
distribution was measured with a 2100 Bioanalyzer (Agilent, Santa Clara,
CA, USA).
Pools of libraries (8/lane) were sequenced (2 × 125 bp paired-end sequencing)
with v4 chemistry on a HiSeq 2500 (Illumina, San Diego, CA, USA). All sequence
library preparation and sequencing were performed by the Centre for Genomic
Research (CGR), University of Liverpool.
Analysis of RNAseq data. RNAseq data were analysed as recently described when
analysing the contribution of the CYP6P9a gene13, including the initial processing
and quality assessment of the sequence data. The Subread aligner version 1.4.633
was used to align the RNAseq R1/R2 read pairs to the reference sequence for which
the annotation was improved using BLAST2GO version 4.0.734.
FeatureCounts version 1.4.635 was used to count the fragments mapped in the
sense orientation to annotated An. funestus genes (automated predictions from
gene set AfunF1.4, downloaded from VectorBase). EdgeR36 was used to analyse the
differential gene expression with pairwise comparisons performed.
The differences in total tag counts among samples were corrected by calculating
normalisation factors using the “TMM” (Trimmed Mean M-values) method in
edgeR36 with default parameters. The P values associated with logFC were adjusted
for multiple testing using the false-discovery rate (FDR) approach37. Differentially
expressed genes were deﬁned as those with an FDR-adjusted P value < 5% and>
twofold absolute difference in expression level. Tag counts and the total CDS
lengths were used to calculate the fragments per kilobase of gene sequence per
million mapped reads.
Further analyses of the RNAseq data were performed using the Strand NGS
software (Strand Life Sciences, version 3.0) following RNA alignment and RNA-seq
analysis pipeline with standard parameters. Genes differentially expressed in each
country and between different countries (generated from Venn diagrams) were
detected using DESeq normalisation with a FC > 2. Multiple test correction used
Benjamini–Hochberg method with a false discovery rate of 5% (adjusted P value <
0.05).
Quantitative reverse transcriptase PCR. The expression patterns of the most
differentially expressed detoxiﬁcation genes between countries (Cameroon,
Uganda, Malawi, Ghana and Benin) were validated using qRT-PCR. The primers
are listed in Supplementary Table 4. Total RNA was extracted from three biological
replicates from mosquitoes that survived 1 h exposure to permethrin in each
country. One microgram was used as the template for cDNA synthesis using
Superscript III (Invitrogen) with oligo-dT20 and RNase H according to the
manufacturer’s instructions. The qRT-PCR ampliﬁcation was performed following
standard protocol11,38 after establishing the standard curves for each gene to assess
PCR efﬁciency and quantitative differences between samples using serial dilution.
The relative expression level and FC of each target gene was established for
comparisons to Cameroon; these were calculated according to the 2−ΔΔCT method
incorporating the PCR efﬁciency39 after normalisation with the housekeeping
genes ribosomal protein S7 (RSP7; AFUN007153) and actin 5C (AFUN006819).
Analysis of CYP6P9b polymorphism patterns Africa-wide. Due to the high up-
regulation of CYP6P9b, the polymorphism of its 5′UTR between CYP6P9b and
CYP6P5 was analysed by amplifying and sequencing a 1-kb fragment, following
same protocol as for CYP6P9a18 in 15 mosquitoes in different regions of the
continent. This included southern (Mozambique, Malawi and Zambia), central
(DR Congo and Cameroon), eastern (Kenya and Uganda), and western Africa
(Benin, Nigeria and Ghana) and in the two laboratory strains FANG and FUMOZ.
The primers are presented in Supplementary Table 4. ClustalW40 was used to align
the sequences, and the polymorphisms were identiﬁed in DnaSPv5.1041. The
maximum likelihood tree was constructed using MEGA 7.0 with bootstrapping
(500 replicates)42.
The 1 kb 5′UTR fragment of CYP6P9b was also ampliﬁed in mosquitoes
collected in Mozambique before the scale up of bed nets (pre-intervention) in 2000
and in mosquitoes collected in 2016 in the same region after the deployment of
long-lasting insecticidal nets in these countries. The PCR products were cloned and
sequenced, and the sequencing data was analysed as described above while also
constructing a haplotype network using TCS43.
Promoter activity of 5′-ﬂanking region sequences of CYP6P9b. To investigate
the regulatory regions controlling CYP6P9b, the intergenic region between this
gene and the preceding gene CYP6P5 was used to design primers (6P9dplF and
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6P9a/b) to amplify this region in the laboratory colonies FANG and FUMOZ. The
PCR products were then cloned in to PJET1.2 (Thermo Scientiﬁc, St. Leon-Rot,
Germany) and sequenced using the Pjet1.2 forward and reverse sequencing
primers.
The promoter activities of the 5′-ﬂanking region sequences were evaluated
using a luciferase reporter assay. Primers (KpnI_6P9bF1.0 and HindIII_6P9a/b)
were used to amplify the 5′-ﬂanking region sequences for the resistant and the
susceptible strains cloned in Pjet1.2 and then sub-cloned into the PGL3-basic
(Promega, Madison, WI, USA) ﬁreﬂy luciferase vector between the Kpn1 and
Hind111 restriction sites to form the recombinant promoter PGL3 for testing.
The recombinant constructs were transfected in An. gambiae cell line 4a-2 cell
line (MRA-917 MR4, ATCC® Manassas Virginia) maintained at 25 °C in
Schneider’s Drosophila medium supplemented with 10% heat inactivated foetal calf
serum and 1% penicillin/streptomycin. One day prior to transfection, about 5 × 105
cells were plated in each well of 24-well plates and allowed to reach 60–70%
conﬂuence. At about 60% conﬂuence, the constructs were introduced in the cells
using Qiagen Effectene Transfection Reagent by co-transfecting 600 ng
recombinant reporter constructs (CYP6P9b 5’ﬂanking region in pGL3-Basic),
LRIM promoter in pGL3 and pGL3 without promoter with 1 ng actin-Renilla
internal control in 60 ml DNA condensation buffer, 4.8 ml enhancer and 6 ml
Effectene in triplicates. Two independent replicates were carried out. Two days
after incubation at 25 °C, the cells were washed with PBS and lysed in 100 ml
passive lysis buffer (Promega); a luminometer (EG & G Berthold) was used to
measure the luciferase activity, which was normalised to Renilla luciferase activity.
To localise the enhancer elements responsible for the up-regulation of CYP6P9b
in the resistant as opposed to the susceptible populations, progressive 5′ deletion
fragments of the 5′ ﬂanking region from −978 to +97 (from the predicted
transcription start site) was performed. Serially deleted fragments −630 to +97,
−440 to +97, −181 to +97 and −128 to +97 were constructed using
HindIII_6P9a/b common reverse primer, and each of the forward primer
KpnI_6P9bF(1.0), KpnI_6P9bF(0.6), KpnI_6P9bF(0.4), KpnI_6P9bF(0.3) and
KpnI_6P9bF(0.1) was tested to check if the deleted fragments −978 to −631, −630
to −441, −440 to −182 and −181 to −129 enhanced the promoter activity.
Design of PCR-RFLP diagnostic for CYP6P9b genotyping. The SNP-RFLPing
244 tool was used to design a PCR-RFLP that could discriminate between the
CYP6P9b promoter of the resistant (FUMOZ) and the susceptible (FANG) strains.
Primers 6P9brﬂp_0.5F and 6p9brﬂp_0.5R were designed to amplify a region in the
promoter common both to FUMOZ and FANG. Each PCR reaction was performed
in a 15-µL volume consisting of 1× buffer A, 25 mMMgCl2, 25 mM dNTPs, 10 mM
of each primer 1U KAPA Taq polymerase (Kapa Biosystems, Boston, MA, USA).
The following PCR ampliﬁcation conditions were used initial denaturation step of
3 min at 95 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 58 °C, and 60 s at 72 °C
with 10 min at 72 °C for ﬁnal extension according to the KAPA kit instructions.
Five microlitre of the PCR product was digested by adding 1 µL of CutSmart buffer
0.2 µL of Tsp45I restriction enzyme (New England Biolabs) and 3.8 µL of water.
The mix was incubated at 65 °C for 2 h. The digested product was migrated on 2%
agarose and stained with Midori Green Advance DNA Stain (Nippon genetics
Europe GmbH) and visualised using a gel imaging system to conﬁrm the product
sizes; there was one band at 550 bp for the resistant (undigested) sample and two
bands at 400 bp and 150 bp for the susceptible samples.
To validate the robustness of the PCR-RFLP to detect the pyrethroid resistance
in the ﬁeld population, the F8 progeny from a cross between highly resistant
(FUMOZ) and highly susceptible (FANG) strains previously used for QTL
mapping14 were genotyped and correlated with the resistance phenotype
established using the odds ratio and Fisher’s exact test.
The pattern of geographical distribution of the resistant allele of CYP6P9b allele
across the continent was assessed by genotyping the CYP6P9b_R in 30–50 ﬁeld-
collected females of An. funestus from several countries in Africa using the DNA-
based diagnostic assay.
Impact of CYP6P9b-on LLINs’ efﬁcacy using hut trials. The study was per-
formed in Mibellon (6°4′60″ N and 11°30′0″ E)—a village in the Adamawa region
of Cameroon where 12 experimental huts have recently been built with concrete
bricks following the speciﬁc design for experimental hut from the West Africa
region45.
The study used a hybrid An. funestus strain generated from reciprocal crossing
between the highly pyrethroid resistant strain FUMOZ-R (CYP6P9b_R) and the
fully susceptible FANG strain (CYP6P9b_S)9. The F5 and F6 generations were used
for the release experiments in the huts after the initial reciprocal crossing between
the laboratory susceptible (FANG and resistant (FUMOZ) strains using 50 males
and 50 females of both strains. The susceptibility of these strains to insecticides is
reported by Weedall et al13 using pyrethroids (0.75% permethrin and 0.05%
deltamethrin), DDT (4%) and the carbamate and bendiocarb (0.1%) according to
WHO protocol45.
The following three treatments were compared in the experimental huts: (i)
untreated polyethylene net; (ii) PermaNet 2.0® (deltamethrin incorporated into
polyethylene net); and (iii) PermaNet 3.0® (PBO+Deltamethrin incorporated into
polyethylene net). To simulate a worn net, six 4 cm × 4 cm holes were made on
each net according to WHO guidelines. The hybrid FANG/FUMOZ strain was
released in each hut for 6 nights (80 mosquitoes per hut).
Three adult volunteers were recruited from the Mibellon village to sleep under
the nets and collect mosquitoes in the morning. Each volunteer provided a written
consent to participate in this study and were also given chemoprophylaxis during
the trial. Ethical approval was obtained from the National Ethic Committee of the
Ministry of the Health in Cameroon.
Mosquito collection was performed in the morning by each volunteer in their
respective room using glass tubes. Mosquitoes were collected in three compartments
including the main room (the walls, ﬂoor and the hut ceiling), inside of each net and
in the exit traps (veranda). A single bag was used for each compartment to avoid the
risk of mixing samples from different areas. A sugar solution was provided to
mosquitoes found alive and they were kept in paper cups for 24 h to assess the
delayed mortality. The status of collected mosquitoes was recorded in observation
sheets either as alive/blood fed, dead/blood fed, alive/unfed and dead/unfed.
An untreated net was used as control to estimate the effect of each treatment by
assessing several parameters including the induced exophily (the proportion of
mosquitoes exiting the room early through the exit traps), the mortality rates
(which provides an indication of the potential mass killing effect of the bed nets)
and the blood feeding rate (which estimates the level of personal protection).
A direct comparison to the untreated control net was used to establish the effect
of both treated nets. A logistic regression model using the Wald statistic that
follows a chi-squared distribution (with df= 1) was used to assess the statistical
signiﬁcance of the difference.
The CYP6P9b_R resistance allele was genotyped in a subset of each treatment
to determine the impact of the CYP6P9b-mediated metabolic resistance to
pyrethroids on the effectiveness of the bed nets. The following were included: the
dead, alive, blood-fed, and unfed mosquitoes in the veranda, in the net and in the
room. The association between the mutation and the performance of each net was
assessed using the Vassar stats (http://vassarstats.net/) with a 2 × 2 contingency
table for the odds ratio calculation based on Fisher’s exact probability test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNAseq: PRJEB24351 and PRJEB10294; CYP6P9b sequences: GenBank MK457459-
MK457689. Data analysed in this study are available on public repositories or available
within the article and its Supplementary Information ﬁles. Further details are available
from the authors upon request.
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